EUR 508.94 For Business Accounts Only

Etude de l'AG du 07/12/2017

In general, Coloplast is in compliance with the Danish regulations relating to the organisation and procedures of the Annual General Meeting.
Under ITEMS 5a-5g, the (re-)election of the board of directors is proposed.
Under ITEM 5a, it is proposed to re-appoint Mr. Michael Pram Rasmussen as Chairman of the board of directors. Although Mr. Pram Rasmussen is deemed independent, ECGS has various other concerns over his re-appointment. Therefore, ECGS normally would have recommended opposition. However, considering that the proxy card does not permit this, it recommends abstention instead.
Under ITEM 5f, it is proposed to re-appoint Mr. Jorgen Tang-Jensen as Member of the board of directors. ECGS has concerns over his aggregate time commitments and therefore normally would have recommended opposition. However, considering that the proxy card does not permit this, it recommends abstention instead.
Under ITEM 6, the board of directors proposes to re-appoint PricewaterhouseCoopers as the Company’s statutory auditor. In light of the substantial amount of non-audit fees, ECGS normally would have recommended opposition. However, considering that the proxy card does not permit this, it recommends abstention instead.
 
Finally, ECGS notes that, since 2011, Coloplast has been named as a defendant in individual lawsuits in various federal and state courts in the US, alleging injury resulting from use of transvaginal surgical mesh products designed to treat pelvic organ prolapse and stress urinary incontinence. During the year under review, Coloplast reached a number of additional agreements related to the lawsuits above and it is estimated that more than 95% of the known lawsuits in the US have now been settled.